GYRE THERAPEUTICS, INC. 8-K

What Happened

• Gyre Therapeutics, Inc. filed a Current Report on Form 8‑K on March 12, 2026 under Item 2.02 to announce its results of operations and financial condition for the fourth quarter and year ended December 31, 2025. The company furnished a press release with those results as Exhibit 99.1 to the filing. The report is signed by Ping Zhang, Executive Chairman and Interim Chief Executive Officer.

Key Details

• Filing date: March 12, 2026 (Form 8‑K, Item 2.02).
• Period covered: Fourth quarter and fiscal year ended December 31, 2025.
• Press release containing the financial results is furnished as Exhibit 99.1 to the 8‑K.
• Signature: /s/ Ping Zhang — Executive Chairman and Interim CEO.

Why It Matters

• The 8‑K notifies investors that Gyre has released its quarterly and full‑year financial results; investors should read the Exhibit 99.1 press release for revenue, earnings, cash position, and any forward guidance or business updates.
• The filing confirms leadership status (Ping Zhang listed as Interim CEO), which is relevant to governance and management continuity while reviewing the financial results.